Plain-English translation of NCT06764875 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new treatment approach for people with advanced stomach cancer that has a specific genetic marker called HER2. The study compares combined with two other cancer medications against the current standard treatment. Researchers want to see which combination helps people live longer and controls their cancer most effectively.
Current treatments for this type of advanced stomach cancer have limited effectiveness, and patients need better options. This trial exists to find out whether this medication can improve outcomes and offer patients a more effective treatment choice.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive one of three treatment combinations, given through infusions or pills. You would visit the study center regularly for dose administration, blood tests, and scans to monitor how well the treatment is working and to check for side effects. The study will continue until your cancer progresses or you experience unacceptable side effects, with follow-up visits to track your long-term health.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
United States